New Liquid Biopsy RAS Testing For Metastatic Colorectal Cancer Patients Now Available For Clinical Practices

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that its OncoBEAM® RAS CRC test has been granted CE Mark approval. The test, developed by Sysmex Inostics GmbH in collaboration with Merck, can now be accessed by patients with metastatic colorectal cancer (mCRC) across Europe. The OncoBEAM® RAS CRC assay has been shown to have similar performance to conventional tissue-based testing[1]-[3] and can be used to determine which patients would benefit from anti-EGFR therapies, such as Erbitux, as demonstrated by recent data.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news